Insider Selling: Cardlytics, Inc. (NASDAQ:CDLX) Insider Sells 5,936 Shares of Stock

Cardlytics, Inc. (NASDAQ:CDLX) insider Nicholas Hollmeyer Lynton sold 5,936 shares of Cardlytics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $3.08, for a total value of $18,282.88. Following the transaction, the insider now directly owns 85,445 shares in the company, valued at approximately $263,170.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cardlytics Stock Performance

Shares of CDLX opened at $3.29 on Friday. The firm has a market cap of $160.50 million, a price-to-earnings ratio of -0.74 and a beta of 1.67. The company’s fifty day moving average is $4.24 and its 200-day moving average is $8.41. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. Cardlytics, Inc. has a 12 month low of $2.89 and a 12 month high of $20.52.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12. Cardlytics had a negative net margin of 50.21% and a negative return on equity of 17.96%. The firm had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. During the same period in the prior year, the business posted ($0.57) earnings per share. The business’s quarterly revenue was down 9.2% on a year-over-year basis. Equities analysts expect that Cardlytics, Inc. will post -1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its position in Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after purchasing an additional 1,774 shares during the period. Canton Hathaway LLC boosted its position in shares of Cardlytics by 95.7% in the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares during the period. Susquehanna Fundamental Investments LLC boosted its position in shares of Cardlytics by 13.8% in the first quarter. Susquehanna Fundamental Investments LLC now owns 31,536 shares of the company’s stock valued at $457,000 after acquiring an additional 3,836 shares during the period. Quest Partners LLC boosted its position in shares of Cardlytics by 160.4% in the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after acquiring an additional 11,061 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Cardlytics in the second quarter valued at approximately $107,000. 68.10% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CDLX has been the topic of a number of research analyst reports. Bank of America downgraded shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $4.00 to $3.50 in a research report on Thursday, August 15th. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and lowered their price target for the company from $18.00 to $5.00 in a report on Thursday, August 8th. Northland Capmk downgraded shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Craig Hallum cut Cardlytics from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.